Korean J Urol.
1992 Apr;33(2):184-192.
In vitro chemosensitivity testing on three-dimensional collagen gel cultured human superficial bladder tumor tissue with doxorubicin, mitomycin-C and cis-platinum
- Affiliations
-
- 1Department of Urology, School of Medicine, Kyung Hee University, Seoul, Korea.
Abstract
-
In vitro testing of cell sensitivity to anticancer drugs that results in en in vivo response is important in both cancer therapy and cancer drug development. The previous studies of in vitro human genitourinary tumors have been limited to established cell lines, short term immunohistochemical and biochemical assays, and immuno-compromised animal implantation. The ability to support the heterogeneous cell population as well as in vivo growth characteristics for in vitro study has been the goal of many investigators. Hoffman has described an assay that offers three-dimensional in vivo-like growth. This three-dimensional culture system is general and grows tumors at high frequencies either directly from surgery or biopsy. They maintain important in vivo properties in vitro. including tissue architecture. According to our studies, the drug responses of cells within the tissue structure of collagen gel supported in vitro-grown tumor tissue that had been obtained from a patient who was clinically confirmed transitional cell carcinoma of the bladder can be determined. In accordance with experimental studies. many human superficial bladder tumor surgical gel specimens that were tested metabolized glucose in a measurable fashion. There was a uniformly steady decline in the control group, which demonstrated a dose responsive suppression of this ability when exposed to effective chemotherapeutic agents. when used by itself, doxorubicin was found to be the most effective drug followed by mitomycin-c. The combination of doxorubicin and mitomycin-c were the most effective drugs followed by doxorubicin and cis-platinum in combination chemotherapy. It was not found that doxorubicin base combination was more effective than doxorubicin single use. Anticancer effect was more dominant during the post-treatment second 72 hours than first 72 hours.